MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
Andrew R. Green(Nottingham Biomedical Research Centre), Emad A. Rakha(Nottingham University Hospitals NHS Trust)
Cited by 125
Related Papers
Artificial intelligence in digital breast pathology: Techniques and applications
|The Breast|2019|200
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
|Breast Cancer Research|2012|126
MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
|British Journal of Cancer|2017|96
Biological and clinical significance of PARP1 protein expression in breast cancer
|Breast Cancer Research and Treatment|2014|83